NEW YORK – Ubiquitome said on Monday that it has signed an exclusive agreement with Switzerland-based market expansion services group DiethelmKellerSiberHegner (DKSH) to market and sell Ubiquitome's mobile PCR-based COVID-19 testing platform Liberty16 in several countries in the Asia-Pacific region.
Under the terms of the deal, DKSH's Singapore-based technology business unit will provide marketing, sales, distribution, logistics, and after-sales services for the Liberty16 in Australia, Cambodia, Indonesia, Laos, Malaysia, Myanmar, New Zealand, the Philippines, Singapore, Thailand, and Vietnam. DKSH will also seek regulatory approval for the device in each of these markets, the company said.
Financial terms of the agreement were not disclosed.
The Liberty16 is a real-time PCR device that amplifies specific target DNA sequences to show the presence of any DNA of interest. It can run 16 tests at once, connects via Bluetooth to its own proprietary iPhone App, is battery-operated, and weighs 2.5 kg. Ubiquitome has suggested that the device's mobility makes it ideal to be used in places like airports to pre-screen international travelers for COVID-19.
Earlier this month, Ubiquitome said it had received NZ$528,927 ($324,388) from the government of New Zealand to help increase its manufacturing capacity for the Liberty16 in Auckland. The company said it also plans to apply for Emergency Use Authorization from the US Food and Drug Administration.